Alvotech plans to resubmit three Biologics License Applications to the U.S. Food and Drug Administration in June 2026 [1].

This regulatory push is critical for the Reykjavik-based company as it seeks to enter the U.S. market with its biosimilar products. Success in these resubmissions would allow the company to begin commercial distribution of high-cost biologics, potentially increasing competition and lowering costs for patients.

The company announced the move following the completion of a routine current Good Manufacturing Practice inspection at its Reykjavik facility [2]. The FDA conducted the surveillance inspection on May 8, 2026 [3]. Alvotech said in a press release on May 11, 2026, that the inspection had concluded [4].

According to the company, the FDA issued a Form 483 containing observations that Alvotech described as manageable [2]. The resolution of these observations is a prerequisite for the agency to move forward with the pending license applications.

Alvotech expects its biosimilar products to receive formal approval by the end of 2026 [1]. However, the timeline remains subject to regulatory scrutiny. Some reports indicate that the FDA has delayed the approval of a key biosimilar, known as AVT05, which has cast doubt on the certainty of near-term approvals [5].

The company's strategy relies on the successful alignment of manufacturing standards in Iceland with U.S. regulatory requirements. The June resubmissions represent the final administrative step before the FDA determines if the products meet safety and efficacy standards for the American public.

“Alvotech plans to resubmit three Biologics License Applications to the U.S. Food and Drug Administration in June 2026.”

The outcome of these three resubmissions will determine if Alvotech can successfully pivot from a developer to a commercial supplier in the U.S. While the company remains optimistic about a year-end approval, the conflicting reports regarding the AVT05 biosimilar suggest that the FDA may still have concerns regarding the company's manufacturing or clinical data.